Shares of Insys Therapeutics, a small-cap biotech with a focus on pain management, plunged as much as 30% on Wednesday after receiving a double whammy.
Tag Archives: Subsys
Arizona’s attorney general is suing Insys Therapeutics over its marketing of the fentanyl opioid spray, Subsys, and that news caused the company’s shares to tumble 18.5% in August, according to S&P Global Market Intelligence.
If you look around, chances are you won’t find many marijuana stocks struggling. But there’s always an outlier — and for the marijuana industry that’s drugmaker Insys Therapeutics.
Here’s why these three cannabis stocks are in better shape than most others in the market. Take a deeper look into GW Pharmaceuticals, Insys Therapeutics, and Aphria.
As of April 13, 2017, more than 10.4 million shares of Insys Therapeutics (NASDAQ: INSY) were sold short. That’s 44% of the marijuana stock’s float. Investors have clearly bet big against Insys, anticipating that the stock will sink.
Insys Therapeutics dropped after it received disappointing news from the DEA regarding its marijuana drug Syndros.
Insys Therapeutics announced a compassionate-use program for its cannabis-based epilepsy drug, igniting optimism that the company is continuing to develop marijuana medicine.
An Arizona opiate maker has given the largest donation to a group working to keep marijuana illegal in the state, according to an article at Tuscon.com. Drug manufacturer Insys Therapeutics made a $500,000 donation to Arizonans for Responsible Drug Policy, according to information from the Arizona Secretary of State’s office.
PHOENIX, Aug. 3, 2016 /Weed Wire/ — Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) today announced financial results for the three-month period ended June 30, 2016.
PHOENIX, May 24, 2016 /Weed Wire/ — Insys Therapeutics, Inc. (NASDAQ: INSY) (“Insys” or “the Company”) today announced that it has successfully completed its Phase 1/Phase 2 safety and pharmacokinetic (PK) study in pediatric subjects with treatment-resistant epilepsy.
Last Wednesday, two pain specialists that were top subscribers of Insys Therapeutics’ (NASDAQ: INSY) leading prescription therapy Subsys were arrested, as part of a year-long operation by the DEA.
In the past few weeks we have seen some massive volatility in the most active cannabis stocks. At the same time we have seen broad market indexes like the NASDAQ and the S&P 500 hit new record highs, begging the question of whether the cannabis stocks are just following general momentum.